Log In
Sunday 26th March 2017

NICE rejects Bayer liver cancer drug again

9th September 2009

The National Institute for Health and Clinical Excellence (NICE) has again rejected Bayer's drug Nexavar for treating liver cancer on the NHS.

This is despite a revised charging scheme from the company and is a further setback to Bayer and its partner Onyx Pharmaceuticals, which have already seen Nexavar turned down by the NICE to treat kidney cancer. Bayer said the decision on its drug, which is known generically as sorafenib, for the treatment of hepatocellular carcinoma was a blow to patients.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2017